Locked and loaded: strong TCR signaling primes anti-PD-1 therapy
Trends in Immunology, ISSN: 1471-4906, Vol: 42, Issue: 12, Page: 1066-1068
2021
- 3Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations3
- Citation Indexes3
- CrossRef3
- Captures12
- Readers12
- 12
Article Description
With continuous T cell receptor (TCR) signaling, T cells can attenuate subsequent antigen responses through adaptive tolerance, thus averting autoimmunity, but potentially also providing refuge to developing cancers. Elliot and coworkers add to our understanding of adaptation via immune checkpoints by exploiting accelerated in vivo adaptive tolerance in the face of strong TCR signaling.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1471490621002362; http://dx.doi.org/10.1016/j.it.2021.10.014; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85118826389&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34772621; https://linkinghub.elsevier.com/retrieve/pii/S1471490621002362; https://dx.doi.org/10.1016/j.it.2021.10.014
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know